Kornimate/medical-research-clean huggingface dataset:
anti-imp3 autoantibody and microrna signature blood tests in finding metastasis in patients with localized or metastatic kidney cancer

Conditions: Kidney Cancer

Summary: this research trial studies the development of a blood test for detecting anti-insulin-like growth factor ii mrna binding protein 3 (anti-imp3) antibody and micro ribonucleic acid (microrna) in patients with renal cell carcinoma (rcc) that has spread to other parts of the body (metastatic) or is limited to the tissue or organ where it began (localized). anti-imp3 is a tumor marker that can be detected in many human cancers, including rcc and is likely to be present in the serum (blood) of patients with metastatic or localized rcc. alterations in microrna expression has also shown to play a critical role in cancer progression and may be a promising biomarker for patients with rcc. developing a blood test for anti-imp3 antibody and microrna in serum and tissue samples of patients in the laboratory may help doctors find and diagnose rcc earlier, find out how far the disease has spread, and plan effective treatment for rcc.

primary objective: i. to develop a blood test by monitoring the titer of imp3 autoantibody and/or microrna (mirna)/small non-coding rna (snrna) expression in patients' serum for the early detection of rcc and its recurrence/metastasis. outline: serum samples are collected prior to treatment and analyzed for anti-imp3 autoantibody titer via enzyme-linked immunosorbent assay (elisa) and total rna via sequencing, microarray, and/or quantitative polymerase chain reaction (q-pcr). previously collected tissue samples are analyzed for imp3 via immunohistochemistry (ihc).

Eligibility criteria:
inclusion criteria: metastatic rcc patients' serum cohort: * a. serum samples from patients with metastatic rcc prior to surgical removal of the metastatic and/or primary lesions * b. serum samples from patients with localized rcc prior to surgical removal of the lesions * c. discarded donors' and patients' discarded/leftover plasma/serum samples from blood bank and other department of pathology laboratories * d. serum samples from patients with metastatic rcc who had nephrectomies or/and rcc-related biopsies in the referring hospitals metastatic rcc patients' tissue cohort: * formalin-fixed paraffin-embedded (ffpe) and/or frozen primary and/or metastatic rcc tissue samples from the corresponding patients serum who are included in inclusion criteria (a-b) * ffpe and/or frozen benign renal tissue samples which are nearby the tumor and remove during surgical procedures from the corresponding patients who are included in inclusion criteria (a-b) * discarded/leftover ffpe and frozen renal tissue samples from department of anatomic pathology and its tumor bank * ffpe primary and/or metastatic rcc tissue samples (unstained slides) from the corresponding patients who are included in inclusion criteria (d) exclusion criteria: not applicable

Keywords: stage i renal cell cancer stage ii renal cell cancer stage iii renal cell cancer stage iv renal cell cancer
distraction osteogenesis in limb-length discrepancy with mesenchymal cell transplantation

Conditions: Leg Length Inequality

Summary: limb-length discrepancy can be due to many causes. these are divided into three groups: congenital (from birth), developmental (from a childhood disease or injury that slows or damages the growth plates), and posttraumatic (from a fracture that leads to shortening of the bone ends). there are three ways to equalize the limb-length discrepancy: use a shoe lift, shorten the long leg, lengthen the short leg. most patients do not like wearing a lift greater than 2 cm (3/4 in). for discrepancies greater than 2 cm but less than 5 cm (2 in), shortening of the long leg can be considered, especially for tall persons. for growing children, this can be easily accomplished with a small, minimally invasive, uncomplicated procedure called epiphysiodesis.the investigators aim to evaluate if injection of bone marrow derived mesenchymal stem cells can shorten the treatment period by acceleration of bone regeneration during distraction osteogenesis.

distraction osteogenesis has been widely utilized to treat leg length discrepancy, deformity, nonunion, osteomyelitis, and bone loss. it has been found that most difficult conditions can be resolved with this method. in this study the aim is to observe if mesenchymal stem cell transplantation can enhance new bone formation during distraction osteogenesis.patients undergo bone distraction , and about 2-3 weeks after distraction mesenchymal stem cell are injected at the callus site. in the case of large bone gap, mesenchymal stem cells are seeded on bone matrix and then placed in the bone gap. each patient is assessed at interval time of 1 month for 6 months post surgery by x-ray and at month 6 post surgery by computed tomography(ct) scans.

Eligibility criteria:
inclusion criteria: * both gender * patient with limb-length discrepancy * age:18-65 exclusion criteria: * diagnosis of cancer,dm,cns disorder,thyroid disease or respiratory disease * known allergic reaction to components of study treatment and/or study injection procedure * patients infected with hepatitis b,c or hiv * pregnancy

Keywords: distraction osteogenesis limb length discrepancy callus
sjogrens syndrome measured by ultrasound

Conditions: Sjogren's Syndrome

Summary: ultrasound study focused on salivary gland outcomes in sjogren's subjects

a 32 week ultrasound study for subject diagnosed with sjogren's syndrome. subjects will receive orencia (abatacept) as intervention therapy during this trial.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with sjogren's syndrome exclusion criteria: * subjects previously diagnosed with sarcoidsis * subjects with positive for hepatitis b, hepatitis c, hiv * subjects diagnosed with cancer within 5 years of screening
evaluating the analgesic efficacy of combined individual nerve block in comparison to interscalene nerve block

Conditions: Postoperative Pain

Summary: patients undergoing total shoulder arthroscopic adhesiolysis may experience severe postoperative pain. inadequate pain management can result in unfavourable hospital outcomes and the development of persistent neuropathic manifestation the aim of the study is to compare both ultrasound techniques (combined individual nerve block to interscalene nerve block) as regards the postoperative analgesic effect and shoulder range of movement.

60 patients will be attached to standard monitoring, will have a secured intravenous line then the skin overlying the procedure area will be sterilized. all patients will be randomly divided into two equal groups; group a will receive ultrasound-guided interscalene block (isnb), and group b will receive ultrasound-guided selective nerve block (snb) of the following nerves; suprascapular nerve block (ssnb), axillary nerve block (anb), lateral pectoral nerve block (lpnb) and musculocutaneous nerve block (mcnb). after delivering the nerve block and confirming sensory blockade by loss of cold sensation, all the patients will receive general anaesthesia with endotracheal intubation using propofol 200mg, atracurium 0.5 mg/kg, 100 micrograms fentanyl. after the procedure ends, the patient will be extubated and transferred to the postoperative anaesthesia care unit. all patients will receive patient-controlled analgesia (pca) in the form ketorolac 30 mg and paracetamol one-gram iv infusion. the following parameter will be assessed and measured; 1. intra-operative inhalation agent consumption 2. intraoperative opioid consumption (fentanyl) if required. 3. duration of postoperative analgesia and time for first rescue analgesia will be recorded. rescue analgesia in the form of 100mg pethidine im and 1 gm paracetamol iv will be given on the first call for analgesia and then repeated on demand. the total dose of pethidine and paracetamol are given throughout the first 24 hours will be recorded. 4. the time for asking for rescue analgesia in the first 24 h and the dose of the analgesic used will also be recorded. 5. the degree of postoperative pain assessed by visual analogue scale (vas) 6. duration of the block: time from completing la injection till complete recovery of sensory function, i.e., the patient feels a cold sensation 7. postoperative range of motion of the operated shoulder 8. patients" satisfaction (yes or no or somewhat satisfied) 9. block-related complications will be also recorded e.g. paraesthesia, and postoperative motor weakness 24 hours after the surgery, pneumothorax and vascular puncture.

Eligibility criteria:
inclusion criteria: * asa i, ii * scheduled for arthroscopic assisted adhesiolysis exclusion criteria: * restrictive lung disease, * refusal of the procedure, * coagulopathy, * allergy to any of the used medications
loss of grip strength, bmi, and adjuvant endocrine therapy breast cancer

Conditions: Breast Cancer; Arthralgia; Obesity

Summary: early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease. typical agents used for treatment include tamoxifen and the aromatase inhibitors. in postmenopausal women, aromatase inhibitor therapy is increasingly common because it is associated with fewer long-term serious toxicities compared to tamoxifen. however, aromatase inhibitors cause arthralgias in 40-50% of patients, which can influence adherence to therapy and can lead to treatment discontinuation in a minority of cases. the mechanism underlying development of this toxicity remains unclear, and predictors of who will develop these symptoms remain undefined. initial reports suggest that grip strength decreases during aromatase inhibitor therapy, and that body-mass index may influence development of this symptom. therefore, this longitudinal study has been developed to determine change in grip strength over time in women treated with aromatase inhibitors and tamoxifen, as well as to identify potential associations between change in grip strength and bmi. patient self-reported symptoms will also be collected. a total of 115 women with early stage breast cancer who are initiating therapy with either an aromatase inhibitor or tamoxifen will be enrolled.


Eligibility criteria:
inclusion criteria: * stage 0-iii breast cancer who are scheduled to receive endocrine therapy with tamoxifen or an aromatase inhibitor * all prior surgery and chemotherapy should be complete * age 18 and above and postmenopausal exclusion criteria: * major rheumatologic disorders * concomitant sex hormone containing drugs or leutinizing hormone releasing hormone agonist therapy * for those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen within 4 weeks of enrollment * for those subjects initiating treatment with tamoxifen, prior aromatase inhibitor within 4 weeks of enrollment

Keywords: joint pain grip strength hormone receptor positive breast cancer
study of intravenous (i.v.) iclaprim versus linezolid in complicated skin and skin structure infections [csssi] (assist-2)

Conditions: Skin Diseases, Bacterial

Summary: the study is now completed

primary objective: the primary objective of this study is to compare the clinical cure rates of iclaprim and linezolid at the test of cure (toc) visit (7 to 14 days after the end of treatment). secondary objectives: the secondary objectives of this study are to compare iclaprim with linezolid regarding: * clinical efficacy at the end of study medication treatment; * time to resolution of systemic and local signs and symptoms of complicated skin and skin structure infection (csssi); * clinical outcome in the microbiologically evaluable (me) population; * bacteriologic outcome in the me population; * bacteriologic eradication rates of baseline (bl) pathogens; * clinical outcome in the modified intent-to-treat (mitt) population; * bacteriologic outcome in the mitt population; * baseline in vitro susceptibility of isolated pathogens in the me population; and * safety and tolerability of iclaprim treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of an infection consistent with complicated skin and skin structure infection due to a gram positive pathogen. exclusion criteria: * known or suspected hypersensitivity to any study medication or other related anti-infective medication * any known or suspected condition or concurrent treatment contraindicated by the prescribing information * previous enrollment in this study * treatment with any investigational drug within 30 days before enrollment

Keywords: skin infection complicated skin infection skin structure infection complicated skin and skin structure infection
eccentric contraction-based resistance exercise for chronic stroke patients

Conditions: Stroke

Summary: the purpose of this study is to develop an evidence-based rehabilitation treatment method suitable for recovery and improvement of physical function in chronic stroke patients using an eccentric overload flywheel device. participants are disabled with chronic stroke (ischemic and hemorrhagic cerebral hemorrhage) over 50 years of age, who can communicate with a korean simple mental state test (mmse-k) of 24 points or higher, and whose functional gait score is 3-5 points. the investigators will enroll 40 participants and randomly assign them to either the control (con, n=20) or the exercise (ex, n=20) group. the investigators will verify the effectiveness of the exercise program through the evaluation of changes in muscle and physical function before and after intervention in both groups.


Eligibility criteria:
inclusion criteria: * patients with disabilities 50 years of age or older who have been diagnosed with a stroke (ischemic and hemorrhagic cerebral hemorrhage) for at least one year * patients can communicate with a korean simple mental state test (mmse-k) of 24 points or higher * patients have a functional ambulation category (fac) score of 3 to 5 exclusion criteria: * patients with brain lesions and quadriplegia excluding stroke * patients with uncontrolled hypertension with limited exercise intervention * patients diagnosed with angina * patients with congestive heart failure (chf) * patients with upper/lower extremity fracture within 6 months

Keywords: eccentric exercise stroke physical function muscle function
comparison and evaluation of ussq, oabss, and the drainage/anti-reflux effect between three kinds of ureteral d-j stents in patients who underwent url

Conditions: Urolithiasis; Overactive Bladder Syndrome

Summary: indwelling double-j ureteral stent (d-j stent) are routinely placed in patients who received ureteroscopic lithotripsy (url) in xinhua hospital urology department. at present, three types of d-j stents, namely cook/kang yi bo(kyb)/urovisionare are used, and usually removed in the day ward four weeks after surgery. this study intends to randomly divide patients with urolithiasis based on the preoperative oabss (overactive bladder symptom score) questionnaire into three groups, namely cook d-j stent group, kyb anti-reflux d-j stent group, urovision trigonal d-j stent group, with corresponding d-j stent indwelled for 4 weeks respectively. the patient's ussq ureteral stent symptom questionnaire）scale and oabss scale were collected at 1 week, 4 weeks (before the removal of d-j stents), and 5 weeks (1 week after removal of d-j stents) after url operation, and the d-j stents removed from the patients were collected, and their drainage and anti-reflux effects were measured in vitro.


Eligibility criteria:
inclusion criteria: 1. abdominal ct scanning indicating ureteral stones or kidney stones that are less than 2 cm in diameter, and patients who are planning to undergo url surgery. 2. age between 18 and 80 years old and capable of providing written informed consent; 3. in general, the heart, lung, liver and kidney function are in well condition, able to tolerate surgical treatment, and comply with research requirements. exclusion criteria: 1. before the onset of urolithiasis, the patient has suffered from obvious overactive bladder syndrome, or chronic lower urinary tract infection, or urinary anatomic deformities, or had previously undergone urinary tract plastic surgery. 2. other severe complications, infections, etc. that the researchers believe may make the subject unsuitable for this study. 3. the patient is not a local resident and insists on returning to his howetown for d-j stent removal after the url operation（so that we are unable to retrieve the d-j stent and conduct the in vitro experiment）. 4. the patient refuses to sign the informed consent.

Keywords: ussq oabss double-j stent ureteroscopic holmium laser lithotripsy
prognostic impact of the evolution of pah 3 months after tavi (htp-tavi)

Conditions: Aortic Valve Stenosis; Pulmonary Hypertension

Summary: aortic stenosis (as) is the most frequent valvulopathy in western countries. the prevalence of as is constantly increasing due to the aging of the population. several studies have shown that pulmonary arterial hypertension (pah) was common in as patients referred for tavi and that it was an independent predictor of mortality after tavi. currently, there is no data in the literature regarding the evolution and prognosis value of pah measured using right heart catheterization (reference method). pah could either regress after tavi or continue to progress despite the treatment of valvulopathy, resulting in a refractory right heart failure that can lead to death. the hypothesis of this study is that patients with pah before tavi procedure and at the 3-month follow-up visit (pah persistence) have an increased risk of cardiovascular mortality compared to patients with no pah at 3 months or having a significant reduction of their pah (pah regression). the aim of the study is to evaluate the prognostic impact of the evolution of pah after tavi in 424 patients using right heart catheterization.


Eligibility criteria:
inclusion criteria: * aortic stenosis * indication of tavi exclusion criteria: * contra-indication of right heart catheterization * pregnancy * persons deprived of their liberty

Keywords: tavi (transcatheter aortic valve implantation) aortic stenosis pulmonary arterial hypertension right heart catheterization
a study of tomato products and disease risk

Conditions: Inflammation

Summary: the purpose of this research study is to test whether certain compounds in tomatoes will help reduce factors in the subject's blood associated with disease risk. the investigators want to know if the tomato-associated compounds will lower or improve the status of these factors, like cholesterol and inflammation. in this research study, the subject will be asked to consume high fat test meals on two separate occasions. the investigators want to see how the subject's body responds to a standard high fat meal, one meal with tomato products and one meal without tomato products. the investigators will measure the subject's blood throughout the study period to determine if consumption of tomato products reduces factors in their blood associated with disease risk.

this study will take three weeks at most, and require one initial screening visit lasting approximately 45 minutes and two study visits each lasting approximately 6 - 8 hours. the investigators are looking for healthy, non-smoking male and female volunteers between the ages of 18 - 65, with no medical history of diabetics, heart, lung, kidney, stomach, or liver disease. the initial screening visit will determine subject' eligibility through height, weight and waist circumference measurements, blood glucose (finger prick) test and a fasting screening blood draw. there will be no compensation for the screening visit, other than transportation costs. if subject qualify, subject will continue to the two study visits. each visit will require subject to have blood drawn several times during subject' study visit (total amount of blood equal to approximately 1 ½ tablespoons). to make this process more tolerable, a registered nurse will place a catheter (similar to what happens when you give blood) into subject's vein for ease in drawing blood. after the catheter placement and the first blood draw, subject will be asked to eat the test meal (tomato or non-tomato meal) and then subject will continue to have blood taken at specific time points for the next 6 hours. the investigators will also do an ultrasound on subject's arm to measure blood flow both before eating and midway through the 6 - hour study visit. the investigators will ask that subject not consume tomatoes or tomato products during the course of the study and record all food and beverages consumed on certain days.

Eligibility criteria:
inclusion criteria: * male and female * between ages of 18-65 * bmi between 19 and 24 and hscrp \< 1mg/l * bmi between 25 and 35 and hscrp \> 2.5mg/l * no clinical evidence of cardiovascular, respiratory, renal, gi or hepatic disease exclusion criteria: * pregnant and/or lactating * allergies or intolerances to foods consumed in the study * fasting blood glucose \> 110mg/dl * taking otc antioxidant supplements, prescription meds that may interfere with study endpoints * unusual dietary habits * actively trying to lose or gain weight * addicted to drugs or alcohol * medically documented psychiatric or neurological disturbances * smoker (past smoker allowed if cessation \> 2 years)

Keywords: tomato nutrition
reaching rural veterans: applying mind-body skills for pain using a whole health telehealth intervention - ug3 pilot

Conditions: Chronic Pain

Summary: this project addresses the significant challenge of providing evidence-based non-pharmacologic pain management to rural-dwelling veterans in the va healthcare system who have chronic pain. for this preparatory phase (ug3) the investigators will conduct a pilot study of 40 rural va patients with chronic pain to assess the feasibility of delivering ramp (experimental intervention for the uh3 trial) in terms of recruitment and engagement, intervention fidelity and adherence, data collection, and other key metrics.


Eligibility criteria:
inclusion criteria: * veteran participants must be rural dwelling * patient's veterans affairs (va) primary care provider is in the southeast region of the us * email address in the va electronic health record (ehr) * report pain at least most days in the past 3 months * brief pain inventory (bpi) pain interference subscale score of 4 or greater * willingness and ability to complete study activities including meeting remotely via videoconferencing when program sessions are held exclusion criteria: * participation in a prior project conducted by the study team on mindfulness for pain (nct0456158) or an engagement activities advisor for the current project * current enrollment in a research study for pain * current enrollment in a similar facilitated, multi-week, multi-modal cih program * severe, poorly controlled psychiatric or substance use disorder (based on chart review using structured checklists, conducted by trained staff who are trained and supervised by a clinical psychologist)

Keywords: chronic pain mindfulness complementary therapies models, biopsychosocial rural veterans health